An analysis argues the TRIUMPH-2 results for Lilly's retatrutide should change how metabolic trials are set up.
Recap by typeshit. Full story at The Clinical Trial Vanguard.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
A new 'In Discussion With' episode features Sehar Shahid on what makes losing weight difficult. Little else is shared beyond the topic.
An investor angle arguing Lilly's triple agonist could become a bigger growth driver than Zepbound, ahead of the company's quarterly report.
Loading…